Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease.

Pinazo MJ, Guerrero L, Posada E, Rodríguez E, Soy D, Gascon J.

Antimicrob Agents Chemother. 2013 Jan;57(1):390-5. doi: 10.1128/AAC.01401-12. Epub 2012 Oct 31.

2.

Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.

Pérez-Molina JA, Sojo-Dorado J, Norman F, Monge-Maillo B, Díaz-Menéndez M, Albajar-Viñas P, López-Vélez R.

Acta Trop. 2013 Aug;127(2):101-4. doi: 10.1016/j.actatropica.2013.04.003. Epub 2013 Apr 11.

PMID:
23583863
3.

Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease.

Alvarez MG, Vigliano C, Lococo B, Petti M, Bertocchi G, Viotti R.

Trans R Soc Trop Med Hyg. 2012 Oct;106(10):636-8. doi: 10.1016/j.trstmh.2012.07.010. Epub 2012 Aug 13.

PMID:
22898619
4.

Adverse events after the use of benznidazole in infants and children with Chagas disease.

Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H.

Pediatrics. 2011 Jan;127(1):e212-8. doi: 10.1542/peds.2010-1172. Epub 2010 Dec 20.

PMID:
21173000
5.

Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease.

Salvador F, Sánchez-Montalvá A, Martínez-Gallo M, Sala-Cunill A, Viñas L, García-Prat M, Aparicio G, Sao Avilés A, Artaza MÁ, Ferrer B, Molina I.

Clin Infect Dis. 2015 Dec 1;61(11):1688-94. doi: 10.1093/cid/civ690. Epub 2015 Aug 11.

PMID:
26265500
6.

Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.

Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, Roddy P, Parreño F, Albajar Viñas P, Palma PP.

PLoS Negl Trop Dis. 2009 Jul 7;3(7):e488. doi: 10.1371/journal.pntd.0000488.

7.

Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.

Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valerio L, Blanco-Grau A, Sánchez-Montalvá A, Vidal X, Pahissa A.

N Engl J Med. 2014 May 15;370(20):1899-908. doi: 10.1056/NEJMoa1313122.

8.

Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.

Altcheh J, Moscatelli G, Mastrantonio G, Moroni S, Giglio N, Marson ME, Ballering G, Bisio M, Koren G, García-Bournissen F.

PLoS Negl Trop Dis. 2014 May 22;8(5):e2907. doi: 10.1371/journal.pntd.0002907. eCollection 2014 May.

9.

Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.

Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A.

Expert Rev Anti Infect Ther. 2009 Mar;7(2):157-63. doi: 10.1586/14787210.7.2.157. Review.

PMID:
19254164
10.

Tolerance of benznidazole in treatment of Chagas' disease in adults.

Pinazo MJ, Muñoz J, Posada E, López-Chejade P, Gállego M, Ayala E, del Cacho E, Soy D, Gascon J.

Antimicrob Agents Chemother. 2010 Nov;54(11):4896-9. doi: 10.1128/AAC.00537-10. Epub 2010 Sep 7.

11.

Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country.

Carrilero B, Murcia L, Martínez-Lage L, Segovia M.

Rev Esp Quimioter. 2011 Sep;24(3):123-6.

12.

[Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará].

de Pontes VM, Souza Júnior AS, Cruz FM, Coelho HL, Dias AT, Coêlho IC, Oliveira Mde F.

Rev Soc Bras Med Trop. 2010 Mar-Apr;43(2):182-7. Portuguese.

13.

Safety of benznidazole use in the treatment of chronic Chagas' disease.

Hasslocher-Moreno AM, do Brasil PE, de Sousa AS, Xavier SS, Chambela MC, Sperandio da Silva GM.

J Antimicrob Chemother. 2012 May;67(5):1261-6. doi: 10.1093/jac/dks027. Epub 2012 Feb 13.

PMID:
22331592
14.

A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.

Sperandio da Silva GM, Mediano MF, Alvarenga Americano do Brasil PE, da Costa Chambela M, da Silva JA, de Sousa AS, Xavier SS, Rodrigues da Costa A, Magalhães Saraiva R, Hasslocher-Moreno AM.

Antimicrob Agents Chemother. 2014 Nov;58(11):6371-7. doi: 10.1128/AAC.02842-14. Epub 2014 Aug 11.

15.
16.
17.

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.

Fernández ML, Marson ME, Ramirez JC, Mastrantonio G, Schijman AG, Altcheh J, Riarte AR, Bournissen FG.

Mem Inst Oswaldo Cruz. 2016 Mar;111(3):218-21. doi: 10.1590/0074-02760150401. Epub 2016 Mar 15.

18.

New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.

Álvarez MG, Hernández Y, Bertocchi G, Fernández M, Lococo B, Ramírez JC, Cura C, Albizu CL, Schijman A, Abril M, Sosa-Estani S, Viotti R.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):833-7. doi: 10.1128/AAC.00745-15. Print 2016 Feb.

19.

Arthritis and benznidazole: more closely related than we thought.

Aldasoro E, Pinazo MJ, Oliveira I, Munoz J, Posada E, Requena-Méndez A, Serret N, Gascon J.

Antimicrob Agents Chemother. 2015 Jan;59(1):727-9. doi: 10.1128/AAC.04078-14. Epub 2014 Nov 10.

20.

Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country.

Murcia L, Carrilero B, Muñoz MJ, Iborra MA, Segovia M.

J Antimicrob Chemother. 2010 Aug;65(8):1759-64. doi: 10.1093/jac/dkq201. Epub 2010 Jun 11.

PMID:
20542903

Supplemental Content

Support Center